Several biomarkers can condition the access to anti-PD-1/PD-L1 ICIs in patients with different advanced cancers such as tumor mutational burden, microsatellite instability, and, more recently, promising mature tertiary lymphoid structures identification [16,17,18]. This evidence concerns the gene CD274 and neoplasm.